本帖最后由 老马 于 2012-1-13 21:20 编辑 7 `" y) J1 i$ ~" r
, R3 a t" m" _7 G" Z1 c4 ^爱必妥和阿瓦斯丁的比较
2 d/ f& `3 a( x- @) o9 L3 k
2 @1 S( r, U0 E: D& Rhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
) z! [& q5 ?3 Y& o8 p3 W
- W1 @$ m" S: u! ~. B: T# z
) U% @' D7 P) E. m8 ~5 J( ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 X7 P2 p. a, L \2 ]$ Q3 X @
==================================================
: F: l5 j& d2 a5 yOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)3 n0 v! O4 X/ m6 ~ P/ H% b4 }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% M5 y5 M4 U* v
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.% A4 f% J9 w1 S* c
|
显身卡
